• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

10.33 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 Next >
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
December 11, 2025
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
November 10, 2025
Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodium 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
November 06, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at Upcoming Investor Conferences
November 04, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
October 30, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 17, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
October 16, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
October 14, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
October 07, 2025
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
September 03, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
August 20, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 15, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
August 13, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
August 06, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
July 30, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
June 18, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
May 20, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
May 08, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
May 06, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
April 29, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
April 23, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Presents Positive Data at APASL 2025
March 26, 2025
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2025
From Aligos Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap